Introduction
Cancer progression and tumor invasion depend critically on many cellular and molecular events, such as the growth and migration of malignant and endothelial cells. Various mechanisms cause a loss of cell adhesion and motility by disrupting basement membrane integrity and degrading the extracellular matrix (ECM). The migration of cancer cells and the formation of metastases depend mostly on neovascularization, and clinical studies have revealed that high vessel density is correlated with poor prognosis (Weidner, 1999) . Tumor angiogenesis is controlled by positive and negative modulators produced by cancer, stromal and infiltrating cells. Many of these modulators are polypeptide growth factors such as fibroblast growth factor-2 (FGF-2 or basic FGF) and vascular endothelial growth factor (VEGF). Endogenous or exogenous in vitro synthesis of FGF-2 stimulates the proliferation and migration of endothelial cells and the production of proteases such as plasminogen activator (PA) and collagenases (Tsuboi et al., 1990) . FGF-2 and VEGF may have synergistic effects on the induction of angiogenesis both in vitro and in vivo. FGF-2 may activate the production of VEGF by endothelial cells, indirectly increasing the switch to angiogenesis in the tumor (Claffey et al., 2001; Seghezzi et al., 1998) . Clinical studies have shown that there is a strong correlation between FGF-2, VEGF levels and vascular density and between metastatic potential and poor survival in human tumors (Giri et al., 1999; Schmidt et al., 1999) .
Interactions between the different tumor cells and the surrounding tissue play a crucial role in tumor growth, invasion, metastasis and angiogenesis. The production of cancer cell-or stroma-derived factors and proteases has a major effect on the early oncogenic process in tumor progression, and often regulates this cascade of events (Chang and Werb, 2001) .
Matrix-metalloproteases (MMPs) and the urokinasetype plasminogen activator/receptor system (uPA/ uPAR) have been shown to be important extrinsic regulators during cancer progression (Dano et al., 1999) . MMPs constitute a family of over 25 proteins that degrade ECM components and often release molecules (growth factors, bioactive fragments of ECM) that regulate the biological activities of cells (Bergers and Coussens, 2000; Nelson et al., 2000) . Many studies have shown a positive correlation between tumor progression and the production of multiple MMPs and their specific endogenous inhibitors called tissue inhibitor of MMPs (TIMPs) (McCawley and Matrisian, 2000) . In many cases, the overproduction of MMP-2 and MMP-9 is correlated with an invasive phenotype in human cancers and 'angiogenic switch' in tumors Fang et al., 2000; Maatta et al., 2000) . The proteolytic system of the plasminogen activator consists of the urokinase serine protease, uPA and its transmembrane receptor, uPAR. Active uPA, linked to its receptor, converts plasminogen to plasmin, which degrades ECM components and the basement membrane, and activates certain MMPs and growth factors. Thus, plasmin production may influence tumor invasion both directly and indirectly (Andreasen et al., 1997; Mazzieri et al., 1997) . PAIs (plasminogen activator inhibitors) are specific inhibitors of uPA/ uPAR. Clinical data for human hepatocellular carcinoma has suggested that uPA, uPAR and PAI are all required for proteolysis during tumor cell invasion and metastasis (Zheng et al., 2000) . Conversely, in a murine model, absence of PAI-1 prevented tumor progression and angiogenesis (Bajou et al., 1998) . The regulation of these two proteolytic systems is complex and may require growth factors. Indeed, FGF-2 has been reported to stimulate the production of MMPs and of uPA/uPAR in cancer and endothelial cells (Miyake et al., 1997; Tsuboi et al., 1990) .
FGFs play significant roles in development, woundhealing and tumor progression (Basilico and Moscatelli, 1992; Powers et al., 2000) . They induce cell motility, proliferation and differentiation in a variety of cell types and favor cell survival. FGF-1 and FGF-2 lack leader sequences for extracellular export, in contrast with other FGFs that are secreted. The interaction of FGFs with specific transmembrane tyrosine kinase receptors FGFRs leads to the transduction of intercellular signals, that can trigger the proliferation and migration of endothelial cells by inducing the production of proteases in vitro (Tsuboi et al., 1990) . These two FGFs increase angiogenic activity in various experimental models (Compagni et al., 2000; Pili et al., 1997) . Experimental approaches and clinical data have also shown that both FGF-1 and FGF-2 may behave as transforming/oncogenic factors and may be involved in tumor progression (Forough et al., 1993; Nesbit et al., 1999; Soslow et al., 1999) .
In this study, we investigated the mechanisms by which FGF-1 and FGF-2 favor tumor progression of experimental carcinoma. Cell lines autocrine or nonautocrine for these growth factors were generated by stable transfections and evaluated for their invasiveness, tumorigenic and angiogenic capacities. We found that autocrine FGF-1 or FGF-2 production promoted (i) cell scattering and cell motility in an invasion assay model, (ii) cell invasiveness closely correlated with an increase in the production and activity of proteases and (iii) tumorigenicity in this model of carcinoma. This study also demonstrated that carcinoma cells autocrine or non-autocrine for FGF-1 or FGF-2 gave rise to highly vascularized tumors indicating that extensive tumor angiogenesis was not necessarily correlated with greater tumor development.
Results
Transfected NBT-II cells produce and secrete FGF-1 or FGF-2 in a biologically active form
The various cells that were used and selected are described in Table 1 . Potentially autocrine cells possess a transmembrane receptor FGFR and produce the growth factor, whereas the non-autocrine cells produce the growth factor but have no functional FGFR. The expected FGF was produced in several selected DFlg25 -FGF-1 and Flg8 -FGF-2 clones ( Figure  1Aa ,b and 1B), but among them only one transfectant for each type was presented for subsequent in vitro and in vivo results: cl37 (DFlg25 -FGF-1) and cl1 (Flg8 -FGF-2) (for cell nomenclature see Table 1 ).
Although neither FGF-1 nor FGF-2 possesses a signal peptide, FGF-2 was detected in the conditioned medium of cells that produced FGF-2 (Figure 2Aa ). The FGF-2 secreted by cl1 cells was biologically active against Flg8 cells but, as expected, had no effect on NBT-II cells (Figure 2Ab,c) . No putative secreted (Savagner et al., 1994; Valles et al., 1990) . Furthermore, epithelial Flg8 cells cultured for 48 h in medium conditioned by bGF22 cells were dissociated whereas polyclonal FGF-2 blocking antibodies abolished this scattering activity of FGF-2 on Flg8 cells (Jouanneau et al., 1997) . Fluorescent aggregates of NBT-II or Flg8 cells were deposited on monolayers of NBT-II cells and of cells producing FGF-1 or FGF-2. As expected, aggregates on NBT-II cells were not dissociated (Figure 2Ba,d ) whereas signaling between FGF-2-producing cells and responsive Flg8 cells resulted in the dissociation of the aggregates upon signaling by the secreted FGF-2 ( Figure 2Bf ). Similar results were obtained with NBT-II or Flg8 aggregates in contact with FGF-1-producing cells, indicating that FGF-1, even though it has no signal peptide, can be also exported and, by paracrine/juxtacrine signaling, can target the transmembrane FGFRs of NBT-II and Flg8 cells, to mediate a cell dissociation signal (Figure 2Bb,e) . Furthermore, control NBT-II cell aggregates were dissociated upon addition of exogenous FGF-1 to the complete medium (20 ng/ml) (data not shown). In addition, we have shown that the NSF14 cell phenotype can be partially reverted by using soluble FGFR1 (Figure 2Ca,b) . Thus, both NSF14 and cl1 cells are autocrine for the FGF they produce.
NBT-II cells autocrine for FGF-1 or FGF-2 acquire a mesenchymal phenotype NBT-II cells producing endogenous FGF-1 exhibit a mesenchymal phenotype in vitro, whereas NBT-II cells producing endogenous FGF-2 remain epithelial, like parental NBT-II cells (Jouanneau et al., 1991 (Jouanneau et al., , 1997 . We also found that cl37 cells were not scattered in vitro (cl17 and cl29 presented the same phenotype) whereas cl1 cells had a mesenchymal phenotype (cl19 presented the same phenotype) (Figure 1Ca,b) . Autocrine production of FGF-2 by cl1 carcinoma cells resulted in a mesenchymal phenotype, similar to that of cells autocrine for FGF-1 (data not shown). This was further demonstrated by immunostaining of the desmosomes, one of the main adhesive junctions between epithelial cells, and of vimentin, an inter- Table 1 ). (B) Immunostaining for FGF-1 (a) and FGF-2 (d) in NBT-II cells. FGF-1 produced by NSF-14 cells (b) and cl37 (c) cells was located in the cytoplasm (red) and the nuclei were stained with DAPI (blue). FGF-2 was detected in the cytoplasm of bGF22 (e) and cl1 (f) cells. Photographs were taken at 6400 magnification, using a fluorescence microscope coupled to a CCD camera. (C) a and b show the live cell morphology (a: cl37; b: cl1) under an inverted microscope at 6200 magnification. Double labeling for desmosomes (green) and vimentin (red) was performed on cl37 (c) and cl1 (d) cells. Nuclei were stained with DAPI (blue). Photographs were taken at 6400 magnification, using a fluorescence microscope coupled to a CCD camera 
Carcinoma cells autocrine for FGF-1 or FGF-2 have enhanced invasive properties
The invasive potential of the cells was determined by a Boyden chamber Matrigel invasion assay. Figure 3A clearly shows that NBT-II carcinoma cells had a modest invasive potential (3% of the cells), whereas the proportion of invasive cells was significantly higher for cells autocrine for FGF-1 or FGF-2 (NSF14 and cl1 cells, P50.05).
NBT-II cells and FGF-producing NBT-II cells produce MMPs and TIMP-2
We investigated MMP production and activity by gelatin zymography. The gelatinolytic activity of progelatinases and gelatinases (MMP-2 and MMP-9) was detected in the conditioned medium of each cell type ( Figure 3Ba ). However, the intensity of the bands corresponding to MMP-9 and MMP-2 activity was higher in cells producing FGF-1 or FGF-2 than in control NBT-II cells. ImageQuant 1 analysis showed that the active form of MMP2 was higher for FGF-1-producing NBT-II cells than for other cell types ( Figure 3Bc ).
We then investigated if MMP-2 activation could occur through interaction with MT1 -MMP and TIMP-2. PCR analyses showed that MT1 -MMP and TIMP-2 were produced in all cell types (Figure 3Ca, b) . Western blotting for MT1 -MMP, using cellular extracts of cells stimulated with concanavalin A (Con A) for 24 h, confirmed the production of MT1 -MMP and the presence of a 120 kDa band, which may correspond to a dimer of MT1 -MMP ( Figure 3Cc ). Western blot analysis of the conditioned media of the cells stimulated for 24 h with Con A showed the production and secretion of TIMP-2 and the presence of a 85 kDa band for all cell types ( Figure 3Cd ). The 85 kDa band may correspond to the TIMP-2/MMP-2 complex. Thus, one of the MMP-2 activating processes may be through MT1 -MMP, as both MT1 -MMP and TIMP-2 were shown to be present.
Carcinoma cells autocrine for FGF-1 or FGF-2 overproduce uPAR and promote uPA activation PCR analyses showed that uPA, uPAR and PAI-1 were produced in all cell types, with higher levels of uPAR production in cells autocrine for FGF-1 or FGF-2 (Figure 3Da ,b). Plasminogen activator production and activity were assessed by zymography ( Figure  3Bb ). Pro-uPA and uPA were produced in all conditioned media but the percentage of the active 
Carcinoma cells autocrine for FGF-1 or FGF-2 have increased tumorigenic capacities
NBT-II cells producing FGF-1 (NSF14 cells) have been reported to induce the formation of large tumors (2 -3 cm 3 diameter) within 2 weeks of injection, whereas NBT-II cells producing FGF-2 (bGF22) display similar tumorigenic behavior to control NBT-II cells (Jouanneau et al., 1997) . In this study, cells autocrine for FGF-2 induced large tumors within 3 weeks, whereas cells non-autocrine for FGF-1, induced tumors similar to those induced by control NBT-II cells, 6 -7 weeks after injection (Figure 4 ). The production of these growth factors in vivo was confirmed by Western Tumors obtained with NBT-II cells producing FGF-1 or FGF-2 display extensive angiogenesis
Tumors derived from NBT-II cells producing FGF-1 or FGF-2 have already been shown to be more vascularized than tumors obtained with control NBT-II cells (Jouanneau et al., 1997) . Von Willebrand factor immunostaining of tumor sections showed that numerous vessels were present throughout the tumors induced by NBT-II cells and their FGF-producing derivatives ( Figure 5A ). However, mean vascular density was significantly higher in all FGF-producing tumors than in control NBT-II tumors ( Figure 5B ). FGF-1 and FGF-2 may increase tumor angiogenesis directly, by targeting endothelial cells, and/or indirectly, by promoting the production of other angiogenic factors such as VEGF. PCR analysis showed that VEGF was produced in vitro by all cell types ( Figure  6A ). We also used PCR to check for the production of VEGF in vivo, using primers that recognize both mouse and rat VEGF cDNAs. VEGF was produced by all tumor types ( Figure 6C ). The PstI and HhaI restriction patterns for tumor VEGF PCR products were compared with those for the VEGF PCR products of NBT-II and NIH3T3 cells ( Figure 6B ). This comparison showed that the VEGF produced by the various tumors was essentially of rat origin ( Figure 6C ). However, it cannot be excluded that some VEGF of mouse origin is produced, since mouse VEGF in the total PCR products cannot be revealed by this approach if the total is less than 10% (data not shown). Immunohistochemistry on frozen tumor sections confirmed the presence of VEGF which is mostly located in tumor islets but also in the stromal environment and in the endothelial cells, as shown with laminin labeling for basal lamina ( Figure 5C ). These results indicate that in the NBT-II in vivo system, VEGF is mostly produced by rat cancer cells, but may also be produced by mouse stromal cells.
Active gelatinases are produced in the various tumors
The production and activity of MMPs are often regulated by cross-talk between stromal and cancer cells. In situ zymography, performed on tumor sections, indicated that active gelatinases are present principally in the carcinomatous areas (Figure 7a,c and d) , consistent with the results of in vitro experiments. This gelatinolytic activity was completely abolished in the presence of the inhibitor 1,10 phenanthroline ( Figure  7b ) and was also associated with stromal cells and tumor vessels (Figure 7e) . Thus, active MMPs are produced in vivo by NBT-II cells and their FGF-producing derivatives, and gelatinolytic activity may be correlated with tumor progression and tumor angiogenesis. for VEGF (red) and laminin (green). Nuclei were stained with DAPI (blue). Photographs were taken at 6250 magnification, using a fluorescence microscope coupled to a CCD camera FGF-1 and FGF-2 in tumor progression and vascularization C Billottet et al Discussion FGF-1 and FGF-2 may be involved in cancer progression and tumor metastasis as a result of their mitogenic and migratory effects on cancer cells, but also due to their angiogenic activity. The production of these factors may be increased in tumors and may be correlated with the degree of malignancy (Giri et al., 1999; Soslow et al., 1999; Takahashi et al., 1992) .
Although it lacks a signal peptide, FGF-2 is detected in the conditioned medium of FGF-2-producing cells and it has been suggested that the molecular system by which it is exported is energy-dependent (Florkiewicz et al., 1995) . It is unclear whether FGF-1 is exported, as FGF-1 was not found in the conditioned medium of FGF-1-producing cells. However, in the presence of adenovirus expressing soluble FGFRs, the tumor angiogenesis through FGF-1 is blocked, clearly demonstrating the secretion and activity of FGF-1 (Compagni et al., 2000) . Our results provide evidence for the secretion of these growth factors as the FGF-1 and FGF-2 produced by NBT-II cells are released and biologically active. Nonetheless, the process of secretion seems to differ between FGF-1 and FGF-2, and in our experimental model, FGF-1 may be directly trapped by the ECM, transmembrane FGFRs or heparan sulfate.
Experiments involving the transfection of various cell types with the FGF-1 and FGF-2 cDNAs have shown that both FGF-1 and FGF-2 have the potential to behave as transforming and oncogenic factors (Jaye et al., 1988; Nesbit et al., 1999) . These experiments suggest that the in vitro and in vivo behaviors of FGF-transfected cells, depend not only on the cell type and amount of FGF produced, but also on the possibility to be exported (Forough et al., 1993; Gately et al., 1995) .
Parental NBT-II cells, and their derivatives that are non-autocrine for FGF-1 or FGF-2, had an epithelial phenotype in vitro. In the presence of FGF-1, NBT-II cells are scattered and motile (Valles et al., 1990) . NBT-II cells autocrine for FGF-1 and FGF-2 acquire a mesenchymal morphology, present a majority of internalized desmosomes and produce vimentin. Migration and invasion tests performed in Matrigel-coated Boyden chambers indicated that all the cells were invasive but that NBT-II cells autocrine for FGF-1 or FGF-2 were significantly more invasive than the other cells. Loss of the epithelial phenotype was correlated Tumor invasion is associated with proteolytic degradation of the basement membrane and the ECM components. Various proteolytic systems are involved in invasive tumors and increases in the production of MMPs, uPA or uPAR are correlated with a more aggressive phenotype in various tumors (Borgfeldt et al., 2001; Maatta et al., 2000) . In addition, it has been reported that FGF-2 can stimulate the production of these proteins in cancer and endothelial cells (Miyake et al., 1997; Tsuboi et al., 1990) .
NBT-II and FGF-producing NBT-II cells expressed and produced these proteases and their natural inhibitors (TIMPs and PAIs). MMP-2 and MMP-9 were produced by all cell types, however cells autocrine for FGF-1 had the highest active MMP-2 ratio. The activation of MMP-2 has been studied by various groups (Kinoshita et al., 1998; Lehti et al., 1998) and recent data have provided evidence for the formation of a ternary complex, MT1 -MMP/TIMP-2/MMP-2, as one of the mechanisms of pro-MMP-2 processing (Hernandez- Barrantes et al., 2000) . Studies with our model did not lead to the direct detection of this ternary complex but did show the presence of MT1 -MMP in cell extracts and the release of free TIMP-2 into the conditioned medium. Thus, the production of MT1 -MMP and TIMP-2 by NBT-II cells may be a determinant to promote pro-MMP-2 activation during tumor progression. At low concentrations, TIMP-2 promotes the binding of pro-MMP-2 to MT1 -MMP and at higher concentrations it may prevent pro-MMP-2 activation. Tumor progression critically depends on the balance between positive and negative regulators (Lehti et al., 1998) .
Pathological studies and basal lamina labeling for laminin have shown that tumors obtained with cells autocrine for FGF-1 or FGF-2 are often undifferentiated, whereas tumors obtained with cells nonautocrine for these FGFs are more differentiated, and resemble parental NBT-II carcinomas. However, most tumors are heterogeneous and may present both features. In situ zymography, performed on NBT-II and FGF-producing NBT-II derivative tumor sections, showed that the fluorescent, digested gelatin was located mostly in carcinomatous areas. We observed no clear difference in gelatinolytic activity between NBT-II tumors autocrine and non-autocrine for FGF-1 and FGF-2. These results correlate with our in vitro results and indicate that gelatinases are produced by all the cell types and are processed to a biologically active form both in vitro and in vivo.
Inactive and active forms of uPA were detected by zymography in all cell types. NBT-II carcinoma cells autocrine for FGFs overproduced uPAR and induced higher levels of pro-uPA activation. Thus uPAR/uPA are direct or indirect targets for FGF signaling in our model, leading to an increase in invasive potential.
These results are consistent with those of other studies reporting that the overproduction of uPAR in some human cancers results in greater tumor growth and metastasis (Borgfeldt et al., 2001; Zheng et al., 2000) . But also it seems likely that other proteases are produced by NBT-II cells or stromal cells and may serve as mediators between the cancer cells and the microenvironment (Bergers and Coussens, 2000; Chang and Werb, 2001) .
Invasion is an important step in tumor progression, which requires the proliferation of cancer cells. Nude mice injected subcutaneously with NBT-II cells autocrine for FGF-1 and FGF-2 developed large highly vascularized tumors within 2 weeks, whereas NBT-II cells non-autocrine for FGFs, like the parental cells, gave rise to tumors that developed several weeks later. These results provide evidence that autocrine FGF-1 and FGF-2 act as tumorigenic factors allowing rapid NBT-II carcinoma development. In previous studies we have reported that NBT-II cells expressing exclusively the nuclear localized 24 kDa -FGF-2 are highly metastatic, but that the tumors obtained were vascularized similarly to those obtained with parental NBT-II cells (Okada-Ban et al., 1999) .
Tumor progression and the incidence of metastasis are correlated with vascular density (Weidner, 1999) . In the NBT-II carcinoma model, the in vivo production of FGF-1 and FGF-2 increases tumor vascularization, whether the production is autocrine or non-autocrine. Thus, tumor proliferation is not necessarily correlated with angiogenic index, and NBT-II tumors are able to activate an angiogenic switch independent of FGF signaling. The angiogenesis observed in NBT-II tumors may be due mostly to the VEGF production of the rat carcinoma cells whereas, in FGF-producing tumors, cumulative paracrine signaling of FGFs and VEGF on endothelial cells probably occurs, increasing tumor angiogenesis. Recent studies have shown that FGF-2 increases the activation of endothelial cells by upregulating VEGF production (Claffey et al., 2001; Seghezzi et al., 1998) . Although we did not detect significant production of mouse VEGF cDNAs in the tumors, the stimulation of endothelial cells by mouse VEGF may occur in vivo.
Gelatinases play a crucial role not only in tumor invasiveness, but also during the tumor angiogenic switch Fang et al., 2000) . Consistent with this, gelatinolytic activities were detected by in situ zymography along the length of the tumor capillaries.
NBT-II cells autocrine for FGF-1 or FGF-2 present similarly high invasive, tumorigenic and angiogenic potentials. As FGF-1 and FGF-2 do not activate the same FGFR, this model does not appear to differentiate between the FGF-1/FGFR2b and FGF-2/ FGFR1 signaling pathways. However, other studies have reported that FGF-1 and FGF-2 are able to induce different functions through different pathways (Boilly et al., 2000) .
Taken together, our studies demonstrate that in the NBT-II experimental carcinoma, extensive tumor Clinical data have shown that malignancy index is often associated with tumor angiogenesis, and recently, angiogenesis inhibition strategies have emerged as approaches for the treatment of cancer. However, tumor development from transformed cells does not depend only on angiogenic factors. Our results indicate that an anti-angiogenic approach to reduce or abolish tumor progression may not be sufficient, as 'basal' vascularization may efficiently support tumor development. Improvements in our understanding of the mechanisms regulating tumor progression may offer new perspectives for designing therapeutic drug targets for the treatment of carcinoma. It seems that the progressive growth of an established tumor beyond initial steps, which require a 'basal' vascularization, is independent of the vascular density (Giavazzi et al., 2001) . This supports the concept that an efficient treatment to inhibit the development of solid tumors should be applied early in tumor progression and that combined administration of anti-angiogenic agents with other inhibitors may provide optimal results for the clinical treatment of certain tumors.
Materials and methods

Reagents
Monoclonal anti-FGF-2 antibodies were purchased from Transduction Laboratories. Monoclonal and polyclonal anti-FGF-1 antibodies were a gift from D Chopin (Hoˆpital Henri Mondor, France) and M Jaye (GlaxoSmithKline Pharmaceuticals, USA), respectively. Monoclonal antibodies against desmosomal proteins, vimentin, and TIMP-2 were purchased from Boehringer, Amersham Pharmacia Biotech, and Oncogene Research, respectively. Polyclonal antibodies against VEGF, and Von Willebrand factor were purchased from Santa Cruz and DAKO, respectively. Monoclonal antibodies against MT1 -MMP were provided by MC Rio (LGME, France) Polyclonal anti-laminin antibodies, protease inhibitor cocktail, Matrigel, PKH26 cell labeling kit, concanavalin A (Con A), tetrazolium salt MTT (3-[4,5-dimethyl-thiazol-2-y]-2,5-diphenyltetrazolium bromide), gelatin, plasminogen, casein were purchased from Sigma. Phosphatase inhibitor cocktail was purchased from Calbiochem. Texas Red-conjugated sheep anti-mouse IgG orconjugated donkey anti-rabbit IgG, FITC-conjugated donkey anti-rabbit IgG, horseradish peroxidase-conjugated sheep anti-mouse IgG or -conjugated donkey anti-rabbit IgG (Amersham Pharmacia Biotech), Alexas 488 or Alexas 594-conjugated goat anti-mouse IgG (Molecular Probes) and Texas Red-conjugated donkey anti-goat IgG (Jackson Immunoresearch Laboratories) were used as second antibodies. Heparin and soluble recombinant human FGFR1 extracellular domain were purchased from Leo and Austral Biological Laboratories, respectively.
Cell lines and culture
The epithelial NBT-II cells were derived from a chemicallyinduced rat bladder carcinoma (Toyoshima et al., 1971) . These cells did not produce endogenous FGF-1 or FGF-2, but possessed a high affinity FGF-1 receptor FGFR-2b on their surface. NBT-II derived cells producing FGF-1 (NSF14 cells) or FGF-2 (bGF22 cells) as well as Flg8 cells expressing the high affinity FGF-1 and FGF-2 receptor FGFR1 have been described elsewhere (Jouanneau et al., 1991 (Jouanneau et al., , 1997 . Nonfunctional FGFR expressing cells, DFlg25 cells, generated by stable transfection with a dominant-negative form of FGFR1 (DN-FGFR1), have been reported previously (for cell nomenclature, see Table 1 ). FR3T3 cells (Fisher rat 3T3 fibroblast) provided by F Thierry (Institut Pasteur, France) were used as a positive control for the production of the membrane-type metalloprotease MT1 -MMP. All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (complete medium).
Plasmids and transfection
The pFGF-1 and pFGF-2 expression vectors contain the entire cDNA coding sequence of the human FGF-1 and the bovine 18 kDa-FGF-2, respectively (Jouanneau et al., 1991 (Jouanneau et al., , 1997 . pREP4 contains a hygromycin resistance gene (Invitrogen). To generate NBT-II cells non-autocrine for FGF-1, DFlg25 cells were cotransfected with pREP4/pFGF-1 plasmids (1 : 5 or 1 : 10 molar ratio). NBT-II cells autocrine for FGF-2 were obtained by cotransfection of Flg8 cells with pREP4/pFGF-2 plasmids (1 : 5 or 1 : 10 molar ratio). The in vitro FGF production in hygromycin B resistant clones was analysed by Western blotting on cellular extracts of DFlg25-FGF-1 clones (cl17, cl29 and cl37) and Flg8-FGF-2 clones (cl1 and cl19) (see Table 1 ).
Indirect immunofluorescence staining
Two610
4 cells were seeded on a glass coverslip and grown to subconfluence. For FGF-1 and FGF-2 staining, cells were fixed in 4% paraformaldehyde in PBS (phosphate bufferedsaline: 136 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4), permeabilized with 0.1% Triton-X100 and blocked in 5% fetal bovine serum. Cells were then incubated with mouse monoclonal anti-FGF-2 antibody (1 : 25) or anti-FGF-1 (1 : 100) before staining with Texas Red-conjugated sheep anti-mouse IgG. For desmosomal components and vimentin staining, cells were fixed in methanol and acetone at 7208C, and sequentially incubated with mouse monoclonal anti-desmoglein and anti-desmoplakin antibodies (1 : 25) and then with Alexas 594-conjugated goat anti-mouse IgG. Labeled cells were then incubated with mouse monoclonal anti-vimentin antibody (1 : 5) followed by a second incubation with Alexas 488-conjugated goat antimouse IgG. For VEGF and laminin staining, frozen tumor sections (7 mm) were fixed in acetone at 7208C and blocked with 6% fetal bovine serum in TBS (Tris-buffered saline: 100 mM Tris-HCl, 150 mM NaCl, pH 7.4). Sections were incubated with goat polyclonal anti-VEGF antibody (1 : 25) and rabbit polyclonal anti-laminin antibody (1 : 200). Sections were then incubated with Texas-Red-conjugated donkey anti-goat IgG and FITC-conjugated donkey antirabbit IgG.
Western blot analysis FGF-1 and FGF-2 Serum-free conditioned media, generated after 24 h cell culture, were collected, and subconfluent cells were washed with PBS and scraped off into 2 M NaCl, 0.1 M phosphate buffer pH 7.4 supplemented with protease inhibitor cocktail. Cell lysates and tumor fragments FGF-1 and FGF-2 in tumor progression and vascularization C Billottet et al (approximately 100 mg) were crushed in 2 M NaCl, 0.1 M phosphate buffer pH 7.4 with an Ultraturax and centrifuged at 12 0006g for 15 min. Samples adjusted to a final concentration of 0.5 M NaCl were incubated overnight at 48C with heparin-Sepharose beads equilibrated in 0.5 M NaCl, 0.1 M phosphate buffer pH 7.4. The mixture was centrifuged and the pellet was resuspended in sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol and 0.1% bromophenol blue, 1% b-mercaptoethanol), boiled for 5 min and finally subjected to electrophoresis in a polyacrylamide gel. Proteins were electroblotted onto a PVDF membrane. Membranes were incubated in 3% nonfat milk in TBS for FGF-1 or PBS for FGF-2 and then incubated with either rabbit polyclonal anti-FGF-1 antibody (1 : 500) or mouse monoclonal anti-FGF-2 antibody (1 : 250). The membrane was incubated with horseradish peroxidaseconjugated donkey anti-rabbit IgG or -conjugated sheep anti-mouse IgG.
MT1 -MMP and TIMP-2 Subconfluent cells were incubated for 24 h with serum-free medium in the presence or absence of 50 mg/ml Con A. Cells were scraped into RIPA buffer (1% NP40, 0.5% sodium deoxycholate and 0.1% SDS pH 7.4) supplemented with protease inhibitor cocktail and lysed. Conditioned media were collected and concentrated by a factor of 40 on Vivaspin 20 columns (cut-off 10 000, Vivascience). The lysate was centrifuged at 40006g for 15 min and the supernatant was collected. Fifty mg of protein of lysate or 40 ml of concentrated conditioned medium were treated as described above. The samples were subjected to electrophoresis in a polyacrylamide gel and were transferred. The membrane was blocked with 2% BSA in PBS and then incubated with mouse monoclonal anti-rat MT1 -MMP antibody (1 : 1000) or anti-rat TIMP-2 antibody (1 : 20 Inhibition by soluble FGFR1 In a tissue culture testplate (24-wells), 2610 5 cells per well were grown for 1 week in 500 ml of complete medium supplemented with 50 mg/ml heparin and in the presence or absence of 0.5 mg/ml soluble FGFR1.
Cell invasion assay
Invasiveness was determined in a two-compartment Boyden chamber (8 mm pores) (Transwell, Costar). Complete medium was added to the upper and lower chambers and 5610 4 cells were seeded on the top of the membrane coated with Matrigel (30 mg/200 ml), and incubated for 4 days. The non-invasive cells present on the upper side of the membrane and the invasive cells present on the under side of the membrane and in the lower chamber were counted by means of a colorimetric test using the tetrazolium salt MTT (5 mg/ml). The results, expressed as a percentage of invasive cells were determined from three independent experiments. Statistical significance was determined by a paired Student ttest.
RT -PCR amplifications
Total RNA was isolated from cell lines and tumors by RNA PLUS TM extraction kit (Bioprobes Systems). One mg of total RNA was reverse-transcribed to cDNA using the RNA PCR kit (AMV-RT, Takara Biomedicals). The resulting cDNAs were amplified using specific primers for the genes of interest (see Table 2 ) together with primers for the cDNA of 18S ribosomal RNA subunit. Since VEGF primers recognized both mouse and rat VEGF, VEGF PCR products generated from tumor cDNAs, were digested with HhaI, which cleaves both the mouse and rat VEGF PCR products, or with PstI which only cleaves the rat VEGF PCR products. Each cycle: denaturation at 948C for 1 min, primer annealing at Tm8C and extension at 728C for 1 min. r: rat FGF-1 and FGF-2 in tumor progression and vascularization C Billottet et al
Zymography
Gelatinases (MMP-2 and MMP-9) and PA activities were analysed by specific zymography on serum-free conditioned media, which were concentrated by a factor of 100 on Centricon YM-30 (Polylabo) for gelatin zymography. Samples containing 10 mg of protein were assessed for gelatin zymography, and samples with 0.75 mg of protein for plasminogen zymography. The samples were mixed with sample buffer under non-reducing conditions and subjected to electrophoresis in a polyacrylamide gel containing 0.1% gelatin for gelatin zymography or in a polyacrylamide gel containing 7 mg/ml plasminogen and 1 mg/ml casein for plasminogen zymography. Gels were washed in 37 mM TrisHCl pH 7.6, 2.5% Triton-X100 for 1 h and then incubated in activation buffer (50 mM Tris-HCl pH 7.6, 200 mM NaCl, 5 mM CaCl 2 and 0.02% Brij 35) for 48 h at 378C for gelatin zymography or (100 mM glycine, pH 8.3) for 24 h at 378C for plasminogen zymography. The gels were stained with Coomassie Brilliant Blue R-250, and proteolytic activity was visualized as clear bands against a blue background.
Tumorigenicity in nude mice
Groups of 6-week-old female nude mice (nu/nu Swiss strain, Iffa Credo, France) were subcutaneously injected in the flank with control NBT-II cells or with cells that produced FGF-1 or FGF-2. In each case, a total of 3.5610 6 cells was injected. Tumor volumes were monitored twice per week by caliper measurement. The animals were killed when tumor volume reached approximately 2 cm 3 . Tumors were removed and their angiogenic status was carefully assessed.
Tumor angiogenesis
Fresh tumor fragments were embedded in OCT compound (Tissu-Tek 1 ) and frozen at 7808C until use. Seven mm sections were fixed in acetone at 7208C and permeabilized in 0.25% NP 40 in PBS. Sections were satured with 5% nonfat milk, incubated overnight at 48C with rabbit polyclonal antiVon Willebrand factor antibody (1 : 1000), and then incubated with Texas-Red-conjugated donkey anti-rabbit IgG. The mean vascular density was estimated by counting the labeled vessels on four different areas of each section (by two independent individuals). Statistical significance was determined by a paired Student t-test.
In situ zymography
Location of MMP gelatinolytic activity within the tumors was investigated by in situ zymography with the EnzCheck Gelatinase Assay Kit (Molecular Probes), as previously described (Oh et al., 1999) . This non-fluorescent substrate is subject to intramolecular quenching. Gelatinase activity releases the FITC-gelatin peptides, which become fluorescent. The areas in which gelatinolytic activity occurs can then be identified by fluorescence. Unfixed frozen tumor sections (7 mm) were stained with DAPI in reaction buffer (0.05 M Tris-HCl, 0.15 M NaCl, 5 mM CaCl 2 and 0.2 mM NaN 3 , pH 7.6). They were washed once with reaction buffer, overlaid with 50 ml of fluorescein conjugate DQ gelatin (40 mg/ml in reaction buffer) and incubated overnight at 378C in a humid chamber. The same procedure was also performed in the presence of 250 mM 1,10 phenanthroline inhibitor, as a negative control.
